Abstract-Accumulation of amyloid ␤-peptide (A␤) in the central nervous system (CNS) may initiate pathogenic cascades mediating neurovascular and neuronal dysfunctions associated with the development of cerebral ␤-amyloidosis and cognitive decline in patients with Alzheimer disease (AD) and with related familial cerebrovascular disorders. Whether A␤-related pathology in the CNS is reversible or not and what key therapeutic targets are controlling A␤/amyloid levels in the aging brain remain debatable. In this article, we summarize recent evidence why the receptor for advanced glycation end products and low-density lipoprotein receptor related protein 1 in the vascular CNS barriers are critical for regulation of A␤ homeostasis in the CNS and how altered activities in these 2 receptors at the blood-brain barrier may contribute to the CNS A␤ accumulation resulting in neuroinflammation, disconnect between the cerebral blood flow and metabolism, altered synaptic transmission, neuronal injury, and amyloid deposition into parenchymal and neurovascular lesions. We briefly discuss the potential of advanced glycation end products and low-density lipoprotein receptor related protein 1-based therapeutic strategies to control brain A␤ in animal models of AD and ultimately in patients with AD and related familial cerebrovascular ␤-amyloidoses. Key Words: acute care Ⅲ Alzheimer disease Ⅲ amyloid ␤-protein Ⅲ blood-brain barrier C ontinuous removal of amyloid ␤-peptide (A␤) species from the central nervous system (CNS) is important for preventing their potentially neurotoxic accumulations in brain interstitial fluid (ISF). At the critical threshold concentrations in brain ISF, A␤ may initiate differential pathogenic cascades mediating neurovascular and neuronal stress and ultimately the development of cerebral and neurovascular ␤-amyloidosis and dementia in patients with Alzheimer disease (AD) and related A␤-disorders. A␤ is produced by almost all cells in peripheral tissues and by all types of cells in the CNS, but A␤'s physiological functions still remain unknown.
C ontinuous removal of amyloid ␤-peptide (A␤) species from the central nervous system (CNS) is important for preventing their potentially neurotoxic accumulations in brain interstitial fluid (ISF). At the critical threshold concentrations in brain ISF, A␤ may initiate differential pathogenic cascades mediating neurovascular and neuronal stress and ultimately the development of cerebral and neurovascular ␤-amyloidosis and dementia in patients with Alzheimer disease (AD) and related A␤-disorders. A␤ is produced by almost all cells in peripheral tissues and by all types of cells in the CNS, but A␤'s physiological functions still remain unknown.
There is little evidence that normal brain aging results in local overexpression of the A␤ precursor protein (APP) and overproduction of A␤. 1 A relatively small number of AD patients may have increased A␤ production in the CNS because of inherited mutations in the APP gene nearby the A␤ coding region (ie, Swedish mutation) or presenilins 1 or 2 genes. 2 However, the majority of patients with so-called nongenetic or late-onset AD and patients with familial forms of cerebrovascular ␤-amyloidoses do not have increased A␤ production or APP overexpression in the CNS. These patients likely exhibit a failure in A␤ clearance from the CNS because of either deficient transport efflux mechanisms for A␤ at the blood-brain barrier (BBB) 3, 4 or its faulty degradation in the CNS. 5 Alternatively, an increased influx of circulating A␤ across the BBB may result in A␤ brain accumulation or its deposition in the CNS. 3, 4, 6 Regulation of A␤ levels in Brain ISF Normal A␤ concentrations in brain ISF are carefully maintained by numerous pathways including (1) A␤ production in peripheral tissues, its systemic clearance and production in the CNS; (2) rapid receptor-mediated transport exchanges of free unbound A␤ between brain and blood and across the BBB; 7, 8, 9 (3) the ability of A␤ carrier proteins (eg, apolipoprotein E [apoE], apoJ, ␣2-macroglobulin, transthyretin, and albumin) to bind and sequester A␤ in different extracellular fluid compartments, including plasma, brain ISF, and cerebrospinal fluid (CSF), or to influence its transport across the biological membranes isolating these compartments, including the BBB; 3,7,10,11 (4) A␤ degradation by a variety of proteases, including enkephalinase, 12 insulinase, plasmin, tissue plasminogen activator, or matrix metalloproteinases; 5 (5) continuous slow removal of A␤ through the ISF-CSF bulk flow into the bloodstream; 13 and (6) oligomerization 2 and aggregation 14 of A␤ in the CNS.
Increased A␤42 levels in brain ISF result in formation of neurotoxic A␤ oligomers and progressive synaptic, neuritic, and neuronal dysfunction. 2 Alternatively, A␤ may form neurovascular or cerebral amyloid aggregates. 14 In particular, missense mutations inside the A␤ sequence associate with vascular deposits and cerebral amyloid angiopathy. 14 The development of cerebral amyloid angiopathy and parenchymal amyloid lesions in AD models is further substantially influenced by apoE and apoJ genes. 15 Studies in AD models suggested that A␤ brain efflux measurements may be useful for quantifying brain amyloid burden in patients at risk for or those who have been diagnosed with AD. 8 For example, the intravenous administration of m266 monoclonal anti-A␤ antibody results in rapid efflux of A␤ from the CNS into plasma of plate-derived growth factor-driven mice increasing plasma A␤ to low nanomolar levels within 24 hours. 8 The development of plaques in these mice 16 and in senescent nonhuman primate models of cerebrovascular 17 and parenchymal ␤-amyloidosis 18 may shift the A␤ transport exchanges between the CNS and its peripheral pool toward the brain.
Peripheral A␤ Pool
Circulating A␤ pool reflects A␤ contributions from peripheral tissues and organs, on the one hand, and the CNS, on the other. Although the concentrations of free A␤ in brain ISF are Ϸ6-fold higher than in plasma under physiological conditions, 19, 20 the absolute amounts of free A␤ in body fluids available for transport exchanges at the BBB are Ϸ10-fold greater than the absolute amounts of A␤ in the brain ISF and CSF.
Increased levels of free A␤ in plasma have been reported in AD mouse models 21 or after treatment with A␤-peripheral binding agents. 8, 9, 22, 23 In AD patients, plasma A␤ levels are elevated and mainly incorporated into lipoproteins and different plasma proteins. 24, 25 The levels of circulating A␤42 and A␤40, after acid denaturation and chromatographic separation of A␤ carrier proteins in AD, are 54 nmol/L and 8.6 nmol/L, respectively, 25 whereas free A␤ in the peripheral venous blood represents only a minute fraction of total plasma A␤ (ie, between 60 and 120 pmol/L). 19 
A␤ Transport at the BBB is Dominated by Receptor for Advanced End Glycation Products and Low-Density Lipoprotein Receptor Related Protein 1
The BBB in vivo does not allow free exchanges of polar solutes such as A␤ between brain and blood, or between blood and brain, because of the presence of a continuous monolayer of brain endothelial cells that are zipped by tight junctions which effectively isolate brain ISF-CSF compartments from the plasma compartment. 26 Therefore, specialized receptors at the BBB must exist to shuttle A␤ across the brain endothelium from CNS into the bloodstream or from blood into the CNS. The receptor for advanced end glycation products (RAGE) and low-density lipoprotein receptor related protein 1 (LRP) remain the most interesting targets, as demonstrated by their ability to rapidly transport circulating free A␤ into the CNS 9 and brain-derived A␤ into the blood, 7,30 ( Figure 1 ). Based on transport modeling with A␤40, 7,9 one can calculate that in healthy brain, if influx shut down, LRP efflux could remove all soluble A␤ at physiological levels from brain ISF in Ϸ1 minute (Figure 1 ). On the other hand, if efflux shut down, RAGE influx could replace all soluble A␤ in brain ISF by plasma A␤ in Ϸ40 minutes. The high excess capacity demonstrated in the LRP efflux system casts general doubt on theories of increased brain production of A␤ as the genesis of late-onset AD.
The possible implications for AD can also be seen from similar transport calculations. For example, if influx shut down, LRP efflux (assuming it remains normal) will be able to remove all soluble A␤ from brain ISF at increased levels as seen in AD at Ϸ12 nmol/L 19 in Ϸ40 minutes. If one speculates that all insoluble A␤ at pathological levels in the brain could be resolubilized, then based on the transport modeling with A␤40, it would take Ϸ65 hours to remove 4 mol/L per kilogram of resolubilized A␤ (Figure 1 ). On the other hand, if efflux shut down, RAGE influx (if not blocked) could at Ϸ2 nmol/L A␤ plasma levels replace all soluble A␤ in brain ISF (Alzheimer levels) in Ͻ2 hours and may create an increment in A␤ levels in brain ISF at a rate of Ϸ0.15 mol/L per kilogram per day.
RAGE/A␤ Interactions at the BBB
RAGE is a multiligand receptor in the immunoglobulin (IgG) superfamily, which binds soluble A␤ and mediates pathophysiologically relevant cellular responses consequent to ligation by a variety of ligands. 27 RAGE is implicated in development of Alzheimer neurovascular disorder by mediating A␤ transcytosis across the BBB, 9,29 by inflammatory and procoagulant responses in endothelium, 9, 27 and by promoting apoptosis through nuclear factor B-dependent mechanism, 28 as shown in Figure 2 . Our recent study has demonstrated that RAGE mediates transport of pathophysiologically relevant concentrations of A␤ into the CNS. 9 After Figure 1 . Brain ISF A␤ concentrations are regulated by rapid RAGE and LRP-mediated transport at the BBB. RAGE-mediated influx and LRP-mediated efflux for A␤ across the BBB were based on kinetic modeling with A␤40 in mice. 7, 9 Normal brain ISF A␤ levels derived from direct ISF measurements in mice, 15, 20 whereas the CSF levels in AD patients 19 and the ISF levels in mouse AD models 15, 20 were used to approximate brain ISF A␤ levels in AD assuming the CSF and ISF concentrations are comparable. Normal plasma concentrations of free A␤ in nondemented patients (0.05 to 0.12 nmol/L) derived from several studies. 19 The reported plasma levels for A␤40 and A␤42, after acid denaturation and chromatographic separation of plasma proteins in AD patients, were 54 nmol/L and 8.6 nmol/L, respectively. 25 BBB transport, circulating A␤ is rapidly taken up by neurons inducing cellular stress, whereas RAGE/A␤ interaction in brain endothelium results in elaboration of endothelin-1, a potent vasoconstrictor, and in suppression of the blood flow. 9 
LRP/A␤ Interactions at the BBB
LRP is a multiligand lipoprotein receptor which interacts with a broad range of secreted proteins and resident cell surface molecules (eg, apoE, ␣2M, tissue plasminogen activator, plasminogen activator inhibitor-1, APP, factor VIII, and lactoferrin), mediating their endocytosis or activating signaling pathways through multiple cytosolic adaptor and scaffold proteins. 30 LRP has been linked to AD genetically 31 and may influence APP processing and metabolism and A␤ uptake by neurons through ␣2M. 32 Because APP mice overexpressing functional LRP minireceptors in neurons have increased levels of soluble A␤ in the brain, 33 it is unlikely that LRP on neurons in vivo mediates A␤ clearance.
Recent studies indicate that LRP is expressed in brain capillary endothelium, 7, 34 and that LRP along the brain capillary membranes in vivo clears A␤40 into the blood. 7 Because the formation of A␤ complexes with either apoE or ␣2M has not been shown in the CNS in vivo during rapid clearance transport studies, 7 it is possible that LRP interacts directly with A␤, and that this interaction may result in rapid clearance of A␤ on brain capillaries. 35 
RAGE and LRP-Based A␤-Lowering Strategies
Drugs that downregulate RAGE and upregulate LRP at the BBB may have a capability to readjust the transport equilibrium for A␤ by promoting its efflux from brain into the bloodstream. In AD and in APP transgenic models of AD, RAGE is significantly upregulated at the BBB, 7,29 whereas LRP is downregulated. 7 Whether overexpression of RAGE influences the expression of LRP is currently unknown. Our recent findings demonstrate that RAGE-specific IgG can increase the expression of LRP in human brain endothelial cells exposed to A␤-rich environment by blocking the effect of A␤ on RAGE receptor, suggesting the activities of the 2 receptors may be linked ( Figure 3A) . On the other hand, drugs that may upregulate LRP by acting directly on BBB endothelial cells, as we illustrate for the 2 statins (ie, simvastatin and lovastatin; Figure 3B and 3C), may also help in clearing A␤ from brain.
The high binding affinity of A␤ to RAGE and LRP may offer a basis for development of soluble products that can act as peripheral or central binding agents for A␤. An example of this is sRAGE, a truncated form of the RAGE receptor that does not contain the cytoplasmic domain of the receptor but does contain the V-type binding domain and is able to significantly reduce development of cerebral ␤-amyloidosis in an AD mouse model. 9 Another example could be soluble LRP fragments that bind directly A␤. 26 Thus, future preclinical studies in APP animal models of AD should show whether RAGE and LRP-based strategies to modify A␤ transport exchanges at the BBB will have a major impact on clearing A␤/amyloid across the BBB, with an ultimate goal to provide a safe therapy to control cognitive decline in AD and related cerebrovascular disorders.
